The-Infinity-Center-Soft-Layout-mgc

CALL TODAY With fast turnaround time, easy, convenient web-based interface and clear and understandable reporting we provide you the opportunity of better patient care. The Infinity Treatment Center is a special health outpatient clinic for individuals struggling with opioid dependency r abuse.

83 C Michael Davenport Blvd. Frankfort, KY 40601

502-352-2300

www.infctr.com

www.infctr.com 83 C Michael Davenport Blvd. Frankfort, KY 40601 502-352-2300

INTERVIEW 1 ________________________________

INTERVIEW 2 ________________________________

Single Page Ad

Single Page Ad

The Infinity Treatment Center specializes in outpatient care for individuals struggling with addiction and substance abuse.

www.infctr.com

502-352-2300

www.infctr.com

INTERVIEW 3 ________________________________

Two-Page Ad

www.infctr.com

individuals can become addicted even after only taking opioid pain meds for a few days. One study found that one in five people given a 10-day supply of opioid painkillers became long-term users. More M.D. Education Needed Don Teater, M.D., medical adviser of the non-profit National Safety Council, says doctors need more education to understand the draw- backs of prescribing opioids. “Doctors get a lot of training in the physical aspects of health, but not the mental aspects,” says Teater, a family physician in North Carolina whose practice focuses on treatment of pain and the treatment of opioid use disorder. “We don’t get training in addiction. Often, a doctor will start a patient on opioid pain med- ication and continue it for awhile. Then if the doctor feels the patient is asking for too much medication, the doctor will cut them off, and abandon them. There needs to be a greater understanding of the emotional component to pain. We also need to have a better under- standing of the disease of addiction.” According to a white paper from the Council, there is little evidence that opioids are helpful when used for chronic pain.

four groups – and by similar levels: 4.3 points in the ibuprofen/acetaminophen group, 4.4 points in the oxycodone/acetaminophen group, 3.5 in the hydrocodone/acetaminophen group and 3.9 in the codeine/acetaminophen group. The researchers said the major limitation of the study is that it had the patients assess their pain only while they were in the emergency department. The study did not evaluate how the ibuprofen/acetaminophen combination would work in comparison to opioids once the patients went home. Also, the participants had a specific type of acute pain – from sprained or broken arms and legs. “Preventing new patients from becoming addicted to opioids may have a greater effect on the opioid epidemic than providing sus- tained treatment to patients already addicted to opioids, in whom it may take many years to achieve recovery,” Demetrio Kyriacou, M.D., a senior editor at JAMA and a professor of emer- gency medicine at Northwestern University, wrote in an accompanying editorial. Yet, as Kyriacou also acknowledges, “stemming the opioid addiction crisis will … require reex- amination of the long-standing assumptions that opioids are superior to

Trial evaluated effectiveness for common injuries

Four Groups of Patients The patients were randomly assigned to one of four groups. One group received a pill for their acute pain that contained a combination of ibu- profen and acetaminophen, the ingredients in Advil and Tylenol. The other groups were given a pill for their pain that contained a prescription opioid as well as acetaminophen, either oxyco- done and acetaminophen (Percocet), hydroco- done and acetaminophen (Vicodin), or codeine and acetaminophen (Tylenol No. 3). All the patients were asked to rate their pain immediately before taking the pain medication and again both one and two hours afterward (before they left the emergency department). The assessments were done using an 11-point scale (0 = no pain; 10 = worst possible pain). The study found that the intensity of pain was similar among all four groups before they took the medication, with a mean score of 8.7 on the scale. The pain then declined over time in all

As the over prescribing of opioid pain medications has become a major public health concern, health care providers have been paying more attention to over-the count- er-drugs that could be used instead, without the risk of addiction. A recent study published in the Journal of the American Medical Association (JAMA) has confirmed that OTC meds ibuprofen and acet- aminophen are just as effective as prescription opioids at reducing acute pain caused by com- mon injuries.It is one of the few “real world” studies that has made the comparison. A team of researchers led by Andrew Chang, M.D. of Albany Medical College, studied 411 patients (aged 21 to 64) who had sought med- ical care at two urban emergency departments after having sprained, strained or broken an arm or leg. (About 20 percent of the patients had fractures.)

non-opioids in most clinical situations requiring man- agement of moderate to severe pain.” Studies have shown that nearly one-third of adult patients seeking care at U.S. hospital emergency departments are given prescriptions for opioid painkillers, even if their visit was not pain-relat- ed. That is a dangerous practice, since some

“In fact, some evidence shows they may be detri- mental and increase risk of addiction and premature death,” the paper says.

There is little evidence that opioids are helpful when used for chronic pain.

It also authorizes HHS to develop grants to support people who are in recovery transition to independent living and jobs, as well as develop a pilot program to provide temporary housing for those recovering from substance abuse. of the bill provides measures to prevent synthetic opioids like fentanyl from entering the U.S. According to the Centers for Disease Control, total opioid deaths did not increase in 2017, but deaths due to fentanyl overdoses did. Data shows the drug, which is about 50 times more potent than heroin, caused nearly 30,000 fatal overdoses last year. access to medication-assisted treatment. It removes the cap on the number of patients to whom drugs like buprenorphine, a drug cravings and easing withdrawal, from 100 to 275, and expands a grant program allowing medication-assisted treatments.

strengthen the federal government’s response to the opioid crisis,” Sen. Rob Portman (R-OH), who helped put together the legislation, said in a statement after the Senate vote. “Importantly, this bill will increase access to long-term treatment and recovery while also like fentanyl from being shipped into the United States through our own Postal Service.” On the other side of the debate, Leana Wen, M.D., the former health commissioner of Baltimore (and incoming president of Planned Parenthood), said that the legislation “is simply tinkering around the edges.” Daniel Raymond, director of policy and planning for the Harm a bad thing, but I do think to some degree it’s a political document,” Raymond told the Washington Post. “When you drill down into it, it’s not that there aren’t good ideas, but it doesn’t reach the level of, this is what our nation needs right now.” and Mental Health Services Administration (SAMHSA) to allow organizations to develop opioid recovery centers in a community. It also requires the Department of Health and Human Services to determine best practices and then create a grant program implementing those policies or procedures, such as the use of recovery coaches, which has

On October 24, 2018... President Trump signed a new, bipartisan bill to combat the opioid addiction epidemic. Politicians are hailing it as a major step forward, while addiction and treatment experts say it falls far short of

A package of more than 70 bills introduced targeting the opioid crisis, the Support for Patients & Communities Act:

• Reauthorizes funding from the Cures Act, which put $500 million a year toward the opioid crisis, and makes some policy changes intended to give states more • Creates a grant program for “Comprehensive Opioid Recovery Centers,” which will attempt to serve the addiction treatment and recovery needs of their communities (in part by using what’s known as an ECHO model). • Removes restrictions on medications for opioid addiction, allowing more types of health care practitioners to prescribe the drugs.

• Expands an existing program

• Advances new initiatives to educate and raise awareness about proper pain treatment among health care providers. • Attempts to improve coordination between different federal agencies to stop illicit drugs like fentanyl at the border, and gives agencies more tools to improve detection and testing at border checks. • Increases penalties for drug manufacturers and distributors related to the over-prescribing of opioids.

responders, such as police and

naloxone, a medication that reverses opioid overdoses.

• Allows federal agencies to pursue more research projects related to addiction and pain. • Makes several changes to Medicare and Medicaid to attempt to limit the over-prescription of opioid painkillers within the programs and expand access to addiction treatment, including lifting some of the current restrictions that make it harder for Medicare and Medicaid to pay for addiction treatment.

INDUCTION PHASE The first phase of Suboxone treatment, "induction," must be supervised by a physician. It begins once a person enters the early stages of withdrawal. The physician will prescribe the medication and try to find the lowest dose that will reduce the person's use of other opioids without causing withdrawal symptoms, serious side effects, or cravings. If a person takes Suboxone prior to entering the early stages of withdrawal or has other opioids in his or her system, the medication can cause acute feelings of withdrawal. STABILIZATION PHASE As soon as cravings for opioids subside and side effects deminish, the second stage begins. The prescribing physician may adjust dosing during this stage. MAINTENANCE PHASE The next phase is called "maintenance." Under direction of the physician, the patient will continue to take medication as prescribed and seek counseling or other forms of behavioral therapy. This stage of treatment also begins a medically supervised withdrawal from Suboxone, gradually reducing the dose to smooth the transition and reduce the likelihood of relapse. RECOVERY PHASE The last phase is recovery. Ideally, this will include aftercare planning by a case manager or a counselor. Some patients may benefit from ongoing outpatient therapy such as 12-step programs and/or individual or group therapy.

Suboxone can be taken as either a tablet or a film and is placed under the tongue to dissolve. It suppresses both cravings for opioids and withdrawal symptoms, which can help prevent relapse. A single dose blocks the euphoric effects of other opioids for at least 24 hours. When used as prescribed, Suboxone does not cause euphoria. HOW DOES IT WORK? Suboxone is a combination of buprenorphine and naloxone. Naloxone is very effective at blocking the effects of opioid medication. However, it can trigger withdrawal symptoms in people who are taking an opioid, causing effects that range from agitation and irritability, to wild mood swings, insomnia, nausea and vomiting, muscle cramping, and diarrhea. Patients who have been chronically addicted to full opioids like heroin can develop seizures and respiratory failure, which can prove fatal. Therefore, naxolone is combined with buprenorphine, a weak opioid medication. Since buprenorphine triggers the opioid receptors in the brain only partially, the “highs” are quite low in comparison to those created by strong opioids, and they are not as habit-forming. Thus, provides a way for the patient to be weaned off their addiction gradually, minimizing withdrawal symptoms. This makes Suboxone both effective and safer than alternative medications like methadone. SUBOXONE TREATMENT The duration of the various treatment phases should be adjusted according the person's needs. The last 2 stages - medical maintenance and long-term recovery - will be the longest and, in some cases, may need to continue indefinitely. Suboxone’s combination of naloxone and buprenorphine

Suboxone is a medication used to treat opioid addiction, including addiction to heroin and narcotic painkillers. When taken as prescribed, it can be both safe and effective. Suboxone is not a cure for opioid addiction. It should be used as a component of another form of treatment, such as inpatient or outpatient addiction treatment programs that focus on the underlying causes of addiction and reduce the risk of relapse

20

21

Scientists search for the ‘Holy Grail’

FROM ADDICTION

The Infinity Treatment Center of Frankfort, is a special health outpatient clinic for individuals struggling with opioid dependency or abuse. Treatment options include a combination of medication-assisted treatment, counseling, patient education and other approved therapy models. The medication-assisted portion of the treatment uses one of the various formulations of Suboxone® (buprenorphine hydrochloride/naloxone) currently approved by the FDA.

83 C Michael Davenport Blvd. Frankfort, KY 40601 502-352-2300

www.infctr.com

INTERVIEW 4 ________________________________

OPIATE + OPIOID ADDICITON What is the difference between Opiates and Opioids?

OPIATES

OPIOIDS

A Natural Pain RemedIES

SYNTHETIC PAIN MEDICATIONS

VS.

Opium

Oxycodone

Thebaine

Hydrocodone

Morphine

Oxymorphone

Codeine

Hydromorphone

Heroin

What Medications Treat Opiate & Opioid Addiction?

Call toDAY TO speak with one of our specialists Don’tGetHungUp on Prescription Medications

Naltrexone

These medications act directly upon the opioid receptors; more specically the mu receptors. Because the effects of these medications vary at the receptor level, there can be different clinical effects during treatment.

ReVia | Depade | Vivitrol

Methadone Dolophine

Buprenorphine Suboxone | Subutex

A FULL AGONIST binds to the receptor and activates it by changing its shape - inducing a full receptor response.

A PARTIAL AGONIST binds to the receptor and activates it with a smaller shape change in the receptor that includes a partial receptor response.

www.infctr.com

83 C Michael Davenport Blvd. Frankfort, KY 40601

502-352-2300

INTERVIEW 5 ________________________________

INTERVIEW 6 ________________________________

83 C Michael Davenport Blvd. Frankfort, KY 40601 502-352-2300

www.infctr.com

To Learn More about our Programs and Services Call or Visit Us Online

502-352-2300

www.infctr.com

Page 1 Page 2-3 Page 4-5 Page 6-7 Page 8-9 Page 10-11 Page 12-13 Page 14-15 Page 16-17 Page 18-19 Page 20-21 Page 22-23 Page 24-25 Page 26-27 Page 28-29 Page 30-31 Page 32-33 Page 34-35 Page 36

Powered by